Self-assembly of phosphorylated dihydromyricetin as a carrier-free bone targeting nanomedicine with enhanced efficacy for osteoporosis treatment
Osteoporosis (OP) is a common metabolic disease, that mainly affects skeletal system with the features, including reduction bone density, deterioration bone structure, bone pain and increase risk of bone fracture. In this work, a well-known anti-osteoporosis natural compound named as dihydromyriceti...
Saved in:
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2025-07-01
|
| Series: | Materials & Design |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S0264127525005696 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849423001222643712 |
|---|---|
| author | Yanlong Zhong Shaorong Huang Peng Luo Qi Lai Fengbo Mo Xinmin Yang Xiaoyong Zhang Bin Zhang Yen Wei Xiaowei Yang |
| author_facet | Yanlong Zhong Shaorong Huang Peng Luo Qi Lai Fengbo Mo Xinmin Yang Xiaoyong Zhang Bin Zhang Yen Wei Xiaowei Yang |
| author_sort | Yanlong Zhong |
| collection | DOAJ |
| description | Osteoporosis (OP) is a common metabolic disease, that mainly affects skeletal system with the features, including reduction bone density, deterioration bone structure, bone pain and increase risk of bone fracture. In this work, a well-known anti-osteoporosis natural compound named as dihydromyricetin (DMY) was selected as the model compound to construct a carrier-free bone targeting nanomedicine via a one-step phosphorylation reaction, in which the phenolic groups on DMY were converted into phosphate groups after reacting with phosphorus oxychloride. The resultant phosphorylated DMY (p-DMY) could self-assemble into nanoparticles with excellent water dispersibility and bone targeting capability because of the introduction of hydrophilic phosphate groups. In vitro results demonstrated p-DMY mainly inhibited osteoclast differentiation by blocking NF-κB and MAPK signals in a dose-dependent manner. More interestingly, p-DMY could significantly improve OP treatment efficacy in preventing bone loss and improving the biomechanics of bone tissues as compared with DMY in ovariectomy mice. Therefore, considered the facile synthesis procedure, enhanced OP treatment efficacy as well as negative toxicity of p-DMY, we trust this strategy described in this work should be an elegant tool for construction of natural compounds-based nanomedicines for OP and other metabolic disease treatment. |
| format | Article |
| id | doaj-art-337dec8e8a474603a7796b7c76eb7f03 |
| institution | Kabale University |
| issn | 0264-1275 |
| language | English |
| publishDate | 2025-07-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Materials & Design |
| spelling | doaj-art-337dec8e8a474603a7796b7c76eb7f032025-08-20T03:30:49ZengElsevierMaterials & Design0264-12752025-07-0125511414910.1016/j.matdes.2025.114149Self-assembly of phosphorylated dihydromyricetin as a carrier-free bone targeting nanomedicine with enhanced efficacy for osteoporosis treatmentYanlong Zhong0Shaorong Huang1Peng Luo2Qi Lai3Fengbo Mo4Xinmin Yang5Xiaoyong Zhang6Bin Zhang7Yen Wei8Xiaowei Yang9Orthopedic Hospital, the First Affiliated Hospital, Jiangxi Medical College, Nanchang University, No. 17 Yong Wai Zheng Street, Nanchang, Jiangxi 330006, China; Department of Chemistry, Nanchang University, 999 Xuefu Avenue, Nanchang 330031, ChinaInstitute of Geriatrics, Jiangxi Provincial People’s Hospital &, the First Affiliated Hospital of Nanchang Medical College, Nanchang 330006 Jiangxi, People's Republic of ChinaOrthopedic Hospital, the First Affiliated Hospital, Jiangxi Medical College, Nanchang University, No. 17 Yong Wai Zheng Street, Nanchang, Jiangxi 330006, China; Department of Chemistry, Nanchang University, 999 Xuefu Avenue, Nanchang 330031, ChinaOrthopedic Hospital, the First Affiliated Hospital, Jiangxi Medical College, Nanchang University, No. 17 Yong Wai Zheng Street, Nanchang, Jiangxi 330006, China; Department of Chemistry, Nanchang University, 999 Xuefu Avenue, Nanchang 330031, ChinaOrthopedic Hospital, the First Affiliated Hospital, Jiangxi Medical College, Nanchang University, No. 17 Yong Wai Zheng Street, Nanchang, Jiangxi 330006, China; Department of Chemistry, Nanchang University, 999 Xuefu Avenue, Nanchang 330031, ChinaOrthopedic Hospital, the First Affiliated Hospital, Jiangxi Medical College, Nanchang University, No. 17 Yong Wai Zheng Street, Nanchang, Jiangxi 330006, China; Department of Chemistry, Nanchang University, 999 Xuefu Avenue, Nanchang 330031, ChinaDepartment of Chemistry, Nanchang University, 999 Xuefu Avenue, Nanchang 330031, China; Corresponding authors.Orthopedic Hospital, the First Affiliated Hospital, Jiangxi Medical College, Nanchang University, No. 17 Yong Wai Zheng Street, Nanchang, Jiangxi 330006, China; Corresponding authors.Department of Chemistry and the Tsinghua Center for Frontier Polymer Research, Tsinghua University, Beijing 100084, ChinaOrthopedic Hospital, the First Affiliated Hospital, Jiangxi Medical College, Nanchang University, No. 17 Yong Wai Zheng Street, Nanchang, Jiangxi 330006, China; Department of Chemistry, Nanchang University, 999 Xuefu Avenue, Nanchang 330031, China; Corresponding authors.Osteoporosis (OP) is a common metabolic disease, that mainly affects skeletal system with the features, including reduction bone density, deterioration bone structure, bone pain and increase risk of bone fracture. In this work, a well-known anti-osteoporosis natural compound named as dihydromyricetin (DMY) was selected as the model compound to construct a carrier-free bone targeting nanomedicine via a one-step phosphorylation reaction, in which the phenolic groups on DMY were converted into phosphate groups after reacting with phosphorus oxychloride. The resultant phosphorylated DMY (p-DMY) could self-assemble into nanoparticles with excellent water dispersibility and bone targeting capability because of the introduction of hydrophilic phosphate groups. In vitro results demonstrated p-DMY mainly inhibited osteoclast differentiation by blocking NF-κB and MAPK signals in a dose-dependent manner. More interestingly, p-DMY could significantly improve OP treatment efficacy in preventing bone loss and improving the biomechanics of bone tissues as compared with DMY in ovariectomy mice. Therefore, considered the facile synthesis procedure, enhanced OP treatment efficacy as well as negative toxicity of p-DMY, we trust this strategy described in this work should be an elegant tool for construction of natural compounds-based nanomedicines for OP and other metabolic disease treatment.http://www.sciencedirect.com/science/article/pii/S0264127525005696OsteoporosisPhosphorylated dihydromyricetinBone targetingCarrier-free nanomedicineEnhancement of efficacy |
| spellingShingle | Yanlong Zhong Shaorong Huang Peng Luo Qi Lai Fengbo Mo Xinmin Yang Xiaoyong Zhang Bin Zhang Yen Wei Xiaowei Yang Self-assembly of phosphorylated dihydromyricetin as a carrier-free bone targeting nanomedicine with enhanced efficacy for osteoporosis treatment Materials & Design Osteoporosis Phosphorylated dihydromyricetin Bone targeting Carrier-free nanomedicine Enhancement of efficacy |
| title | Self-assembly of phosphorylated dihydromyricetin as a carrier-free bone targeting nanomedicine with enhanced efficacy for osteoporosis treatment |
| title_full | Self-assembly of phosphorylated dihydromyricetin as a carrier-free bone targeting nanomedicine with enhanced efficacy for osteoporosis treatment |
| title_fullStr | Self-assembly of phosphorylated dihydromyricetin as a carrier-free bone targeting nanomedicine with enhanced efficacy for osteoporosis treatment |
| title_full_unstemmed | Self-assembly of phosphorylated dihydromyricetin as a carrier-free bone targeting nanomedicine with enhanced efficacy for osteoporosis treatment |
| title_short | Self-assembly of phosphorylated dihydromyricetin as a carrier-free bone targeting nanomedicine with enhanced efficacy for osteoporosis treatment |
| title_sort | self assembly of phosphorylated dihydromyricetin as a carrier free bone targeting nanomedicine with enhanced efficacy for osteoporosis treatment |
| topic | Osteoporosis Phosphorylated dihydromyricetin Bone targeting Carrier-free nanomedicine Enhancement of efficacy |
| url | http://www.sciencedirect.com/science/article/pii/S0264127525005696 |
| work_keys_str_mv | AT yanlongzhong selfassemblyofphosphorylateddihydromyricetinasacarrierfreebonetargetingnanomedicinewithenhancedefficacyforosteoporosistreatment AT shaoronghuang selfassemblyofphosphorylateddihydromyricetinasacarrierfreebonetargetingnanomedicinewithenhancedefficacyforosteoporosistreatment AT pengluo selfassemblyofphosphorylateddihydromyricetinasacarrierfreebonetargetingnanomedicinewithenhancedefficacyforosteoporosistreatment AT qilai selfassemblyofphosphorylateddihydromyricetinasacarrierfreebonetargetingnanomedicinewithenhancedefficacyforosteoporosistreatment AT fengbomo selfassemblyofphosphorylateddihydromyricetinasacarrierfreebonetargetingnanomedicinewithenhancedefficacyforosteoporosistreatment AT xinminyang selfassemblyofphosphorylateddihydromyricetinasacarrierfreebonetargetingnanomedicinewithenhancedefficacyforosteoporosistreatment AT xiaoyongzhang selfassemblyofphosphorylateddihydromyricetinasacarrierfreebonetargetingnanomedicinewithenhancedefficacyforosteoporosistreatment AT binzhang selfassemblyofphosphorylateddihydromyricetinasacarrierfreebonetargetingnanomedicinewithenhancedefficacyforosteoporosistreatment AT yenwei selfassemblyofphosphorylateddihydromyricetinasacarrierfreebonetargetingnanomedicinewithenhancedefficacyforosteoporosistreatment AT xiaoweiyang selfassemblyofphosphorylateddihydromyricetinasacarrierfreebonetargetingnanomedicinewithenhancedefficacyforosteoporosistreatment |